Don't Ignore The Insider Selling In ANI Pharmaceuticals

We'd be surprised if ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shareholders haven't noticed that the Senior Vice President of Generics, Ori Gutwerg, recently sold US$305k worth of stock at US$60.00 per share. On the bright side, that sale was only 5.1% of their holding, so we doubt it's very meaningful, on its own.

View our latest analysis for ANI Pharmaceuticals

The Last 12 Months Of Insider Transactions At ANI Pharmaceuticals

The President, Nikhil Lalwani, made the biggest insider sale in the last 12 months. That single transaction was for US$1.1m worth of shares at a price of US$66.10 each. So we know that an insider sold shares at around the present share price of US$60.62. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

In the last year ANI Pharmaceuticals insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

Insider Ownership Of ANI Pharmaceuticals

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. ANI Pharmaceuticals insiders own 9.1% of the company, currently worth about US$112m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

What Might The Insider Transactions At ANI Pharmaceuticals Tell Us?

Insiders sold ANI Pharmaceuticals shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. It is good to see high insider ownership, but the insider selling leaves us cautious. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 1 warning sign for ANI Pharmaceuticals you should be aware of.

Of course ANI Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.